Precision BioSciences (DTIL) CEO sells 34,799 shares to cover RSU taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Precision BioSciences President and CEO Michael Amoroso reported routine equity activity tied to vesting of restricted stock units (RSUs) and related tax withholding. On January 20, 2026, RSUs covering 8,888, 37,069, and 69,421 shares vested and were converted into an equal number of common shares.
On January 22, 2026, Amoroso sold 34,799 shares of common stock at a weighted average price of $4.17 per share, in multiple trades between $3.97 and $4.30. The filing states these sales were made under a pre-arranged Rule 10b5-1 plan and were solely to cover tax withholding and fees from the RSU vesting. After these transactions, he directly held 196,154 common shares, plus 37,069 and 69,421 unvested RSUs.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 34,799 shares ($145,112)
Net Sell
7 txns
Insider
Amoroso Michael
Role
President and CEO
Sold
34,799 shs ($145K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 34,799 | $4.17 | $145K |
| Exercise | Restricted Stock Units | 8,888 | $0.00 | -- |
| Exercise | Restricted Stock Units | 37,069 | $0.00 | -- |
| Exercise | Restricted Stock Units | 69,421 | $0.00 | -- |
| Exercise | Common Stock | 8,888 | $0.00 | -- |
| Exercise | Common Stock | 37,069 | $0.00 | -- |
| Exercise | Common Stock | 69,421 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 196,154 shares (Direct);
Restricted Stock Units — 0 shares (Direct)
Footnotes (1)
- Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.30. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
FAQ
What insider transaction did DTIL CEO Michael Amoroso report?
Amoroso reported RSU vesting on January 20, 2026 that delivered 8,888, 37,069, and 69,421 common shares, followed by a sale of 34,799 shares on January 22, 2026.
What RSU activity did the DTIL CEO report on January 20, 2026?
The filing shows vesting and settlement of RSUs into common stock for 8,888, 37,069, and 69,421 shares, each RSU representing one share of common stock.
What is the role of the Rule 10b5-1 plan in this DTIL Form 4?
The Form 4 notes that the sales were executed under a pre-established Rule 10b5-1 trading plan adopted on August 2, 2024, which prearranges trades to help manage insider transactions.